Kura Oncology, Inc. (KURA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.61-22.98%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · KURA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -61.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
KURA — CFO transition
Dated 2026-09-08
CFO — Jennifer Fulk: The filing announces the appointment of an external candidate, Jennifer Fulk, as the new CFO, replacing Troy E. Wilson in that specific role.
Why it matters: The CFO change adds a leadership handoff during the product launch and clinical program build-out.
Watch forThe next company update confirms Jennifer Fulk is the new CFO. The stated cash runway stays the same.
Also watch forThe company reports a delay in the CFO handoff or revises its stated cash runway.
Why it matters: KOMZIFTI revenue rose 57% in Q2. Another increase would support the launch growth story.
Supportive ifQ3 net product revenue is above $9.1 million, with new patient starts above about 115.
Worry ifQ3 net product revenue is $9.1 million or less, or new patient starts fall below about 115.
Why it matters: Cash fell from $580.8 million in Q1 to $519 million in Q2. Management ties runway to KOMET-017 results in 2028.
Worry ifCash and short-term investments fall below $519 million. Collaboration payments do not arrive as planned.
Less concerning ifCash and collaboration payments cover the AML program through KOMET-017 results in 2028.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$188 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $565 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,400 loss on $10,000 · 44.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.